證監會就中信國際前僱員涉內幕交易展開研訊
證監會在市場失當行為審裁處對中信(國際)前執行副總經理胡錦誠展開研訊程序,原因是其涉嫌就華熙生物科技的股份進行內幕交易。
在關鍵時間,胡與一組同事合作進行一項貸款交易,以便向創隆發展有限公司提供資金,讓其能作出將華熙私有化的要約。
證監會指,胡在掌握私有化內幕消息的情況下,在2017年5月22日至6月15日期間,分別透過自己及其配偶名下的證券帳戶買入合共1萬股及126.5萬股華熙股份。待華熙於2017年6月19日就私有化一事發出公告後,胡便分別賣出自己及其配偶名下帳戶內的1萬股及100.75萬股華熙股份,獲利約300萬元。(ca/s)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.